Monday 17 August 2020

A Chinese consortium of CBMG management members has entered into a definitive merger agreement to acquire Maryland-based biopharmaceutical firm Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) has entered a definitive merger agreement, the company said.

Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of cancer and degenerative diseases. The company conducts immuno-oncology and stem cell clinical trials in China using products from its integrated GMP laboratory.